Axsome Therapeutics
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Axsome Therapeutics sits in the top decile of US sponsors by registered trial count (#568 of 15,742 sponsors by registered trial count).
Axsome Therapeutics: 28 sponsored US clinical trials, 6 recruiting.
Axsome Therapeutics sponsors 28 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 20 completed. 21 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Major Depressive Disorder, with 3 trials.
Top-decile sponsor footprint
Axsome Therapeutics ranks in the top decile of sponsors by registered trial count (#568 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
20 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
28 total, page 1 of 1
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
NCT07484217
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
NCT07398417
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
NCT06568367
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
NCT06413433
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
NCT06223880
SUNOSI® (Solriamfetol) Pregnancy Registry
NCT06413420
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
NCT06736509
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
NCT06360419
A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
NCT05972044
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
NCT05557409
Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
NCT05550207
A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)
NCT05113745
A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
NCT05059223
Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration
NCT05008341
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
NCT04947553
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study
NCT04789174
Assessing Clinical Outcomes in Alzheimer's Disease Agitation
NCT04797715
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
NCT04634669
Mechanistic Evaluation of Response in TRD (MERIT)
NCT04608396
Initiating Early Control of Migraine Pain and Associated Symptoms
NCT04163185
Open-Label Safety Study of AXS-05 in Subjects With Depression
NCT04039022
Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)
NCT04068051
A Trial of AXS-05 in Patients With Major Depressive Disorder
NCT04019704
Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)
NCT03881852
Maximizing Outcomes in Treating Acute Migraine
NCT03896009
Assessing Symptomatic Clinical Episodes in Depression
NCT03595579
Addressing Dementia Via Agitation-Centered Evaluation
NCT03226522
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
NCT02741791
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 19 |
| Phase 4 | 2 |
Therapeutic Areas
Where Axsome Therapeutics enrollment is open (later-stage tilt)
6 recruiting of 28 indexed (21% open); 20 completed (71%).
Phase mix: 21 late (III/IV) vs 6 early (I/II) (later-stage heavy).
Top condition: Major Depressive Disorder (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Axsome Therapeutics: open-pipeline peers nationwide
Peers matched on 28 registered trials and 21% open enrollment, not the therapeutic-area sidebar.
Axsome Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 28 trials (± recruiting share)
- Benaroya Research Institute · 28 trials · 14% recruiting
- CAMC Health System · 28 trials · 11% recruiting
- CTI BioPharma · 28 trials · 0% recruiting
- Harvard Pilgrim Health Care · 28 trials · 4% recruiting
Sponsors near 21% open enrollment (± trial volume)
- GOG Foundation · 21% recruiting · 14 trials
- Kettering Health Network · 21% recruiting · 14 trials
- LifeBridge Health · 21% recruiting · 14 trials
- Olympus Corporation of the Americas · 21% recruiting · 14 trials
Related
What to do with this Axsome Therapeutics page
28 registered trials is a research-attention snapshot, not an endorsement of Axsome Therapeutics or any single study.
- 6 of Axsome Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Major Depressive Disorder is the condition Axsome Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Major Depressive Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Axsome Therapeutics pipeline card: 28 registered trials from official public datasets.Report a data error.